Please assess the completion status of the following clinical trial:

Trial Title: Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. At least 60 years of age and diagnosis of previously untreated AML (either de novo or from an antecedent hematologic disorder or therapy related AML)~2. At least 20% blasts by BM biopsy or aspirate~3. ECOG performance status of 0,1,or 2~4. Adequate cardiac, renal and liver function~Key Exclusion Criteria:~1. Uncontrolled DIC~2. Active central nervous system involvement by AML~3. Requiring hemodialysis or peritoneal dialysis~4. Some prior history of heart attack or stroke (depending on how long ago the event occurred)

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All Study Patients (Type: EXPERIMENTAL): * Schedule A: 72 mg/m2 vosaroxin Days 1, 8 and 15~* Schedule B: 72 mg/m2 vosaroxin on Days 1 and 8~* Schedule C: 72 mg/m2 on Days 1 and 4, or~* Schedule C: 90 mg/m2 on Days 1 and 4

Based on this trial design, predict the completion outcome and termination type (if applicable).